• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Oncology

Neoadjuvant chemotherapy does not appear to significantly improve disease-free survival in patients with locally advanced colon cancer

byMelanie Adams, MDandSze Wah Samuel Chan
April 15, 2024
in Chronic Disease, Oncology
Reading Time: 3 mins read
Colonoscopy collage: a woman beside a drawing of the large intestine, a coiled flexible scope and a glass of clear liquid
Share on FacebookShare on TwitterShare on LinkedIn

1. When compared to upfront surgery, neoadjuvant chemotherapy using mFOLFOX or CAPOX did not appear to significantly improve 3-year disease-free survival.

2. When compared to upfront surgery, neoadjuvant chemotherapy using mFOLFOX or CAPOX did appear to be associated with significant pathological downstaging.

Evidence Rating Level: 1 (Excellent)

Study Rundown: In this phase 3, randomized, multicenter trial, 744 patients, with radiologically staged, locally advanced colon adenocarcinoma were randomly assigned to either the experimental, or standard of care group. Patients in the experimental group received 3 months of neoadjuvant chemotherapy with mFOLFOX or CAPOX, followed by surgery, then 3 months of adjuvant chemotherapy. The standard of care group received immediate surgery; those with pathological stage II and III disease received adjuvant fluoropyrdimidine-based chemotherapy. The primary endpoint was disease-free survival at 3 years. Secondary endpoints were R0 resection, pathological complete response (pCR), pathological TNM staging, tumor regression grade (TRG), overall survival (OS), surgical morbidity / mortality, and chemotherapy adverse events. Neoadjuvant chemotherapy with mFOLFOX or CAPOX did not improve disease-free survival when compared to upfront surgery. Neoadjuvant chemotherapy did appear to increase the chances of pathological downstaging and resulted in a 7% pCR rate. Chemotherapy toxicity, as well as surgical morbidity and mortality, were similar amongst both groups, suggesting neoadjuvant chemotherapy may be safe / feasible. Although promising, the OPTICAL trial relied on radiological staging with CT which has its own limitations; furthermore, only 58% of patients in the experimental group completed neoadjuvant chemotherapy, as planned. Further data, with improved pre-operative staging and improved patient compliance is needed to understand potential benefits moving forward.

Click to read the study in the JCO (Journal of Clinical Oncology)

Relevant Reading: Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial

RELATED REPORTS

WGS Oncodetect showed higher recurrence sensitivity than WES Oncodetect in colorectal cancer

Male sex and hispanic ethnicity are associated with increased risk of early-onset colorectal cancer

In-Depth [randomized-controlled trial]: This trial was investigator-initiated and enrolled 744 patients, from 28 Chinese hospitals, between the ages of 18-75, with biopsy proven colon adenocarcinoma. Eligible patients were clinically staged cT4 of cT3, N0-2; patients with non-operable colon cancer, those with recurrent or metastatic disease or those presenting with obstruction, perforation, or significant bleeding, were excluded from the study. Patient characteristics / baseline data were similar between the experimental and standard of care groups; of the 371 eligible patients assigned to the experimental group, 340 went on to receive neoadjuvant chemotherapy (NAC), consisting of either 6 cycles of mFOLFOX6 or 4 cycles of CAPOX. Three-year disease-free survival rates were 82.1% (95% CI, 78.2 to 86.1) in the experimental group and 77.5% (95% CI, 73.3 to 81.9) in the standard of care group (stratified HR, 0.74 [95% CI, 0.54 to 1.03]; log-rank P = 0.07). Three-year overall survival rates were 95.1% (95% CI, 92.8 to 97.4) in the experimental group and 89.6% (95% CI, 86.4 to 92.9) in the standard of care group (stratified HR, 0.42 [95% CI, 0.24 to 0.76]; log-rank P = 0.005). The most common grade 3-4 adverse events related to NAC were neutropenia and anemia. The most common grade 3-4 adverse event related to adjuvant chemotherapy, in both the experimental and standard of care groups, was neutropenia. Surgical approach, intraoperative / postoperative complications, median operating time, and length of postoperative hospital stay were similar amongst both groups. Findings from this study suggest that NAC may be safe in patients with locally advanced colon cancer, but further studies are needed to evaluate the potential impact on disease-free survival.

Image: PD

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: colorectal cancerearly stage colorectal cancerneoadjuvant chemotherapy
Previous Post

2 Minute Medicine Rewind April 15, 2024

Next Post

Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases

RelatedReports

An envelope is being held with a calendar and an illustration of the colon in the background, indicating a reminder for colorectal screening.
2MM Trial Briefs

WGS Oncodetect showed higher recurrence sensitivity than WES Oncodetect in colorectal cancer

October 26, 2026
Quick Take: Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening
Chronic Disease

Male sex and hispanic ethnicity are associated with increased risk of early-onset colorectal cancer

June 29, 2026
Brain health collage: an engraved brain in side view, a branching neuron, a plain brain-slice silhouette and a reflex hammer
Weekly Rewinds

2 Minute Medicine Rewind June 29, 2026

June 29, 2026
Wide international variation in survival for periviable neonates
Weekly Rewinds

2 Minute Medicine Rewind May 25, 2026

May 25, 2026
Next Post
Breast cancer collage of a calm woman in her fifties, a mammography machine, a cup of tea and a blank card

Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases

The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!

The Scan by 2 Minute Medicine®: Patient Zero: Immunotherapy for Brain Tumors?, Over-the-Counter Birth Control, Florida Supreme Court Deals a Devastating Blow to Abortion Access, Schwarzenegger's Post-Pacemaker Update on Instagram

#VisualAbstract: Physician coaching by professionally trained peers help reduce physician burnout and improve well-being

#VisualAbstract: Physician coaching by professionally trained peers help reduce physician burnout and improve well-being

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Pelacarsen lowers lipoprotein(a) but does not reduce major cardiovascular events in patients with established cardiovascular disease
  • Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer
  • CDC reports 5,412 confirmed measles cases in the United States in 2026
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.